The glow of a panther's eyes in the darkness. The zig-zagging of a shark's dorsal fin above the water.

Humans are always scanning the world for threats. We want the chance to react, to move, to call for help, before danger strikes. Our cells do the same thing.

The innate immune system is the body's early alert system. It scans cells constantly for signs that a pathogen or dangerous mutation could cause disease. And what does it like to look for? Misplaced genetic material.

The building blocks of DNA, called nucleic acids, are supposed to be hidden away in the cell nucleus. Diseases can change that. Viruses churn out genetic material in parts of the cell where it's not supposed to be. Cancer cells do too.

"Cancer cells harbour damaged DNA," says Sonia Sharma, Ph.D., an associate professor at the La Jolla Institute for Immunology (LJI).

"Mislocated DNA or aberrant DNA is a danger signal to the cell. They tell the cell, 'There's a problem here.' It's like the first ringing of the alarm bell for the immune system."

Now Sharma and her colleagues have published a new Nature Immunology study describing the process that triggers this alert system directly inside tumour cells.

Their research shows that a tumour-suppressor enzyme called DAPK3 is an essential component of a multi-protein system that senses misplaced genetic material in tumour cells, and slows tumour growth by activating the fierce-sounding STING pathway.

In the world of cancer immunotherapy, the STING pathway is well-known as a critical activator of cancer-killing T cells that kicks off the body's powerful adaptive immune response.

The new study shows that through DAPK3 and STING, the tumour's own innate immune system plays a greater role in cancer immunity than previously appreciated.

"The tumour-intrinsic innate immune response plays an important role in natural tumour growth and cancer immunotherapy response," says Sharma.

Tumours evolve mutations in tumour-suppressor genes that allow them to grow faster than normal tissue.

Discovery of the critical role that DAPK3 plays in the STING pathway highlights a distinct problem in cancer and cancer immunotherapy.

Tumour cells can acquire mutations that allow them to evade the immune system by keeping cells from sensing red flags such as misplaced DNA.

Sharma and her colleagues with the LJI Center for Cancer Immunotherapy, Max-Planck Institute of Biochemistry and UC San Diego found that loss of DAPK3 expression or function in tumour cells severely hindered STING activation.

Their research in mouse models shows that these tumours were hidden from the immune system, and the researchers observed very few cancer-targeting CD8 "killer" T cells in DAPK3-deficient tumours.

As a result, loss of DAPK3 in tumours decreased responsiveness to cancer immunotherapy.

"Tumours lacking DAPK3 grow faster in vivo because they evade the immune system. They are also resistant to certain immunotherapy regimens, including combination therapies using the immune checkpoint blocker anti-PD1 to target anti-tumour T cells," says Sharma.

Pharmaceutical companies are pursuing immunotherapies to activate STING, which are intended to be used in combination with immune checkpoint blockers.

The new findings emphasise the importance of activating STING in tumour cells themselves--to properly set off that early alert system.

"Tumour-intrinsic immune responses are important," says study co-first author Mariko Takahashi, Ph.D., a former LJI postdoctoral associate who now serves at Massachusetts General Hospital Cancer Center.

The researchers are now looking for additional proteins that play a role in the early innate immune response to cancer.

"There are many players in the tumour microenvironment," says Takahashi.

Source: La Jolla Institute for Immunology